



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/986,240	10/19/2001	Johan Weigelt	13425-047001	5027

26161 7590 12/19/2002

FISH & RICHARDSON PC
225 FRANKLIN ST
BOSTON, MA 02110

EXAMINER

DAVIS, DEBORAH A

ART UNIT PAPER NUMBER

1641

DATE MAILED: 12/19/2002

9

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/986,240

Applicant(s)

WEIGELT ET AL.

Examiner

Deborah A Davis

Art Unit

1641

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 August 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-12 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-12 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) <u>8</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Information Disclosure Statement

1. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609 A(1) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claims 2 and 3 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

4. Claim 2 recite that the "labeled amino acid pair AA1-AA2 is unique with a sphere radius of 10 angstroms within the polypeptide or protein" is vague, because it is unclear whether the distance is between the amino acid pair or is the measurement for the entire polypeptide/protein?

5. Claim 3 recite that the "labeled amino acid pair AA1-AA2 is unique with a sphere radius of 50 angstroms with the polypeptide or protein" is vague because it is unclear

Art Unit: 1641

whether the distance is between the amino acid pair or is the measurement for the entire polypeptide/protein?

Claim Rejections - 35 USC § 102

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claims 1, 4-5, and 8-12 are rejected under 35 U.S.C. 102(b) as being anticipated by Yabuki et al (Journal of Biomolecular NMR, 11: 1998).

Yubuki et al anticipates claim 1 in teaching a method for stable-isotope labeling of proteins by cell free synthesis. In this method, a technique that utilizes Ras protein samples in which the main chain carbonyl carbons of one amino acid type (AA1) are labeled with ^{13}C carbons and another amino acid type (AA2) is labeled with ^{15}N are evaluated with HNCO-type NMR and 2D1-H-15N NMR (see NMR measurements, pg 299 and pg. 300, Figure 1). The amino acid Ser³⁹ (AA2) occurs directly subsequent to Asp³⁸ (AA1) as recited in claim 1 (pg. 301, paragraph 1). Yubuki et al evaluates several amino acid labeled pairs by NMR techniques; such as, the amino acids Asp and Ser are labeled in a pair located within the Ras protein (pg. 300, paragraphs 1 and 2). The labeled Ras protein was then complexed with the binder protein Raf RBD, and evaluated with NMR HNCO spectrum and then compared with the results of the NMR spectrum of labeled amino acid pairs (pg. 301, paragraph 1 and pg 302, Figure 3).

Art Unit: 1641

Chemical shift differences such as cross peaks of labeled amino acid pairs of the Ras protein were observed, compared, recorded both by itself and complexed with the Raf RBD, indicating interaction between the labeled Ras protein and the Ras complexed with the binding protein as recited in claim 1 (pg. 300, last paragraph and pg. 301, first paragraph). The Ras-Raf RBD complex has a molecular mass of about 30 kDa as recited in claim 8 (pg. 300, last paragraph). The reference points out that labeled amino acid pair, Pro-Thr is unique in the Ras protein and was identified by the HNCO experiments as recited in claims 4 and 5 (pg. 300, paragraph 5, lines 17-19). This dual labeling technique can be performed on very large proteins such as an entire IgG (binder) molecule with a molecular mass of about 150 kDa, as recited in claim 11 (pg. 296, paragraph 2). Thus, dual labeling and site-directed labeling by cell-free protein synthesis will be useful techniques for analyzing the structures of proteins as recited in claim 12 (pg. 305, last paragraph, last 3 lines).

Claim Rejections - 35 USC § 103

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

9. Claims 2-3 and 6-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Yubuki et al in view of Fesik et al (WO97/18471).

The teachings of Yubuki et al are set forth above and differ from the instant claims by not teaching the the sphere radius of the labeled amino acid pair, the proximity of an active site within the protein, neither does Yubuki mention the result of the above described method is compared to the result of any other binding or activity assay.

However, Fesik et al teaches a method for identifying ligands which bind to a specific target molecule labeled with radioactive isotopes and said ligand binding is evaluated by NMR. Studies were also performed to compare binding constants of ligands to various biomolecules, determined by the NMR method, such as enzymatic, filter binding and gel shift screening assays (pg. 26, lines 18-24 and pg. 27, lines 1-9). An advantage of using NMR in screening assays is the ability to correlate observed chemical shifts from two-dimensional NMR correlation spectra with other spectra projections of target molecule configuration (pg. 24, lines 1-14).

It would have been obvious to one of ordinary skill in the art to incorporate a comparison method of the various assays as taught by Fesik et al into the method of Yubuki et al to compare the binding of ligands to various biomolecules determined by NMR and to also observe chemical shifts from observed by 2-D NMR techniques. With respect to claims 2, 3 and 6, one skilled in the art would recognized that the proximity and spatial orientations of amino acids within a protein can be modified in such a way to get the desired results, especially since it has been held that discovering an optimum value of a result effective variable involves only routine skill in the art. In re Boesch, 617 F.2d 272, 205 USPQ 215 (CCPA 1980).

Conclusion

10. No claims are allowed.

11. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure:


Shaw et al. "Determination of Statherin N-Terminal Peptide Conformation on Hydroxyapatite Crystals" teaches peptide labeling at specific sites on the amino acid.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deborah A Davis whose telephone number is (703) 308-4427. The examiner can normally be reached on 8-5 Monday thru Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on (703) 305-3399. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-

1123.



Deborah A. Davis
CM1, 7D16
December 16, 2002



LONG V. LE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

12/6/02